Sunlenca
Product · Pharmaceutical / drug by Gilead Sciences
HIV-1 treatment in child-resistant oral tablet packaging
Sunlenca is a 300 mg oral tablet medication for HIV-1 treatment, provided in child-resistant blister packs that comply with U.S. consumer product safety standards.
- Languages
- English
- Forms and strengths
- 300 mg Tablets
- Prescription
- Prescription required
- Dosage Strength
- 300 mg
- Form
- Tablets
- Packaging Type
- Blister Packs
- Pack Sizes
- 4-count or 5-count
- 300 mg oral tablets
- Child-resistant blister pack configurations (4-count and 5-count)
- Complies with Poison Prevention Packaging Act (PPPA) standards
Overview
Sunlenca is a pharmaceutical product from Gilead Sciences used for the treatment of HIV-1 infection. It is formulated as 300 mg oral tablets and is supplied in specialized packaging designed for safety. The product is available in child-resistant blister packs containing either 4 or 5 tablets, meeting the requirements of the Poison Prevention Packaging Act (PPPA). Gilead provides general conformity certificates for Sunlenca to ensure compliance with U.S. Consumer Product Safety Commission regulations. This medication is part of Gilead's virology portfolio focused on addressing unmet medical needs in HIV care.
Dosage and Packaging
- Oral Tablets: Sunlenca is available as 300 mg tablets for oral administration.
- Child-Resistant Blister Packs: The medication is provided in child-resistant blister packs containing 4 or 5 tablets.
Use cases
- Healthcare providers prescribe Sunlenca 300 mg tablets for the management of HIV-1 infection in eligible patients.
Specifications
- Forms and strengths
- 300 mg Tablets
- Prescription
- Prescription required
- Dosage Strength
- 300 mg
- Form
- Tablets
- Packaging Type
- Blister Packs
- Pack Sizes
- 4-count or 5-count
Added by AntSpace from public sources (gilead.com).